WEE1 Inhibition by AZD1775 Augments Colorectal Cancer Cells
                    Susceptibility to VE-822-induced DNA Damage and Apoptosis

Ainaz Mihanfar; Faezeh Asghari; Maryam Majidinia

doi:10.1055/a-2499-3067

Drug Research, Table of Contents

Drug Res (Stuttg) 2025; 75(02): 66-75
DOI: 10.1055/a-2499-3067

Original Article

WEE1 Inhibition by AZD1775 Augments Colorectal Cancer Cells Susceptibility to VE-822-induced DNA Damage and Apoptosis

Ainaz Mihanfar

¹Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran

,

Faezeh Asghari

²Immunology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

,

Maryam Majidinia

¹Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran

› Author Affiliations

Abstract

Background

WEE1 is a key tyrosine kinase involved in the cell cycle regulation with potent anticancer effects in various cancer types including colorectal cancer. Recent studies have focused on the potential of combinational inhibition of Ataxia Telangiectasia and Rad-3-related protein (ATR) and WEE1 in increasing apoptosis in cancer cells. Therefore, this study investigates the effects of inhibiting WEE1, by employing AZD1775, on colorectal cancer cellsʼ susceptibility to VE-822-induced DNA damage and apoptosis.

Methods

SW-480 and HT-29 cells were treated with AZD1775 and VE-822, alone and in combination. MTT assay was used to assess cell proliferation and viability. The mRNA levels of ATR, checkpoint kinase 1 (CHK1), WEE1, ribonucleotide reductase (RR) catalytic subunit M1 (RRM1) and RRM2 were measured by qRT-PCR. Cellular γ-(H2A histone family member X) H2AX levels were measured by Western blot. Analyses were conducted using ELISA to assess 8-Oxo-2ʼ-deoxyguanosine (8-oxo-dG) levels. Lactate dehydrogenase (LDH) and ELISA death assays were used to assess apoptosis.

Results

The SW-480 and HT-29 cells have low proliferation rate when treated with VE-822 and AZD1775. The IC50 value for VE-822 was 1.3 μM and 1.6 μM in SW480 and HT-29, respectively. Also, this value for AZD1775 in SW480 was 140 nM and in HT-29 was 185 nM. The expression levels of ATR, CHK1, WEE1, RRM1, and RRM2 were significantly downregulated in both cell lines treated with combination of VE-822 and AZD1775 (P<0.05). DNA damage markers, including γ-H2AX and 8-oxo-dG were upregulated in these cells. Simultaneous treatment with VE-822 and AZD177 increased apoptosis capacity of both cell lines.

Conclusion

The inhibition of WEE1 via AZD1775 potentiated the anticancer effects of ATR inhibitor, VE-822, in combating colorectal cancer via targeting DNA damage.

Keywords

apoptosis - cancer - anticancer drugs

Full Text

References

References
1 Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Translational Oncology. 2021; 14: 101174
2 Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. Jama 2021; 325: 669-685
3 Seeber A, Gastl G. Targeted therapy of colorectal cancer. Oncology research and treatment 2016; 39: 796-802
4 Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal transduction and targeted therapy 2020; 5: 1-30
5 Hagan S, Orr M, Doyle B. Targeted therapies in colorectal cancer – an integrative view by PPPM. EPMA Journal 2013; 4: 1-16
6 Van der Jeught K, Xu H-C, Li Y-J. et al. Drug resistance and new therapies in colorectal cancer. World journal of gastroenterology 2018; 24: 3834
7 Faruk M. Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?. Annals of Medicine and Surgery 2021; 70: 102793
8 Wang Q, Shen X, Chen G. et al. Drug resistance in colorectal cancer: from mechanism to clinic. Cancers 2022; 14: 2928
9 Elbadawy M, Usui T, Yamawaki H. et al. Development of an experimental model for analyzing drug resistance in colorectal cancer. Cancers 2018; 10: 164
10 Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell cycle 2013; 12: 3348-3353
11 Indovina P, Giordano A. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer biology & therapy 2010; 9: 523-525
12 Ghelli Luserna Di Rorà A, Beeharry N, Imbrogno E. et al. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. Journal of hematology & oncology 2018; 11: 1-18
13 Kong A, Mehanna H. WEE1 inhibitor: clinical development. Current oncology reports 2021; 23: 1-8
14 Schutte T, Embaby A, Steeghs N. et al. Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review. Cancer treatment reviews 2023; 115: 102531
15 Qi W, Xie C, Li C. et al. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. Journal of hematology & oncology 2014; 7: 1-12
16 Qi W, Zhang W, Edwards H. et al. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer biology & therapy 2015; 16: 1784-1793
17 Zhou L, Zhang Y, Chen S. et al. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 2015; 29: 807-818
18 Caiola E, Frapolli R, Tomanelli M. et al. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Scientific reports 2018; 8: 1-7
19 Fordham SE, Blair HJ, Elstob CJ. et al. Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood advances 2018; 2: 1157-1169
20 Jin J, Fang H, Yang F. et al. Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer. Neoplasia. 2018; 20: 478-488
21 Al Bitar S, El-Sabban M, Doughan S. et al. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World Journal of Gastroenterology 2023; 29: 1395
22 Ma SC, Zhang JQ, Yan TH. et al. Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Medicine 2023; 12: 11073-11096
23 Yano K, Shiotani B. Emerging strategies for cancer therapy by ATR inhibitors. Cancer Science 2023; 114: 2709-2721
24 Murga M, Campaner S, Lopez-Contreras AJ. et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nature structural & molecular biology 2011; 18: 1331-1335
25 Gilad O, Nabet BY, Ragland RL. et al. Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent MannerATR Suppression with Oncogenic Stress Increases Instability. Cancer research 2010; 70: 9693-9702
26 Reaper PM, Griffiths MR, Long JM. et al. Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nature chemical biology 2011; 7: 428-430
27 Toledo LI, Murga M, Zur R. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nature structural & molecular biology 2011; 18: 721-727
28 Wang Z, Li W, Li F. et al. An update of predictive biomarkers related to WEE1 inhibition in cancer therapy. Journal of Cancer Research and Clinical Oncology 2024; 150: 13
29 Jackson S, Bartek J. The DNA-damage response in human biology and disease. Nature [Internet] 2009; 461: 1071-1078
30 Helleday T, Petermann E, Lundin C. et al. DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 2008; 8: 193-204
31 Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nature reviews Drug discovery 2011; 10: 351-364
32 Qi W, Xu X, Wang M. et al. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochemical pharmacology 2019; 164: 273-282